AVITA director granted RSUs and stock options
AVITA Medical, Inc. director Jeremy Curnock Cook reported equity awards consisting of restricted stock units and stock options granted as part of his compensation.
Rhea-AI Filing Summary
AVITA Medical, Inc. director Jeremy Curnock Cook reported equity awards consisting of restricted stock units and stock options granted as part of his compensation. He received 22,214 RSUs, each representing one share of common stock, which are subject to time-based vesting 12 months after the January 20, 2026 grant date and were approved by stockholders on June 3, 2026. He also received options to acquire 16,133 shares of common stock at an exercise price of $3.77 per share, exercisable starting January 20, 2027 and expiring January 20, 2036. Following the RSU award, his direct common stock holdings, including unvested RSUs, total 62,050 shares, and he holds 16,133 stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 38,347 shares
Grant/Award
2 txns
Insider
COOK JEREMY CURNOCK
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 16,133 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 22,214 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to Buy) — 16,133 contracts (Direct);
Common Stock — 62,050 shares (Direct)
Footnotes (3)
- F1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F2. Includes unvested RSUs.
- F3. On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
Key Figures
RSU grant size: 22,214 RSUs
Option grant size: 16,133 options
Option exercise price: $3.77 per share
+4 more
7 metrics
RSU grant size
22,214 RSUs
Restricted stock units granted January 20, 2026, time-based vesting after 12 months
Option grant size
16,133 options
Stock options to buy common stock granted January 20, 2026
Option exercise price
$3.77 per share
Exercise price equals Nasdaq closing price on January 20, 2026
Option vesting date
January 20, 2027
Options become exercisable one year after the grant date
Option expiration
January 20, 2036
Final expiration date of granted stock options
Shares held after award
62,050 shares
Total direct common stock holdings after RSU grant, including unvested RSUs
Derivative holdings after grant
16,133 options
Total stock options held after the award, all from this grant
Key Terms
restricted stock units, RSUs, Stock Options (Right to Buy, exercise price, +2 more
6 terms
restricted stock units financial
"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Options (Right to Buy financial
"Stock Options (Right to Buy) with an exercise price equal to the closing price"
exercise price financial
"an exercise price equal to the closing price of a share of Common Stock on Nasdaq"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
time-based vesting financial
"that are subject to time-based vesting criteria. These RSUs vest on the date 12 months"
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
non-executive directors financial
"approved a grant of 16,133 options ... to each of its non-executive directors"
Non-executive directors are board members who do not work for the company day-to-day but oversee management, like an independent referee watching a game rather than playing. They matter to investors because they provide impartial checks on executive decisions, help shape long-term strategy, monitor risks and financial reporting, and guard shareholder interests—contributing to better governance and reducing the chance of mismanagement or conflicts of interest.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did AVITA Medical (RCEL) director Jeremy Curnock Cook acquire in this Form 4?
Jeremy Curnock Cook received equity compensation awards, not open-market purchases. He was granted 22,214 restricted stock units and options over 16,133 shares, both tied to AVITA Medical common stock, with specific vesting and option terms disclosed.
How many restricted stock units did the AVITA Medical (RCEL) director receive?
He was granted 22,214 restricted stock units. Each RSU represents a contingent right to receive one share of AVITA Medical common stock, subject to time-based vesting that occurs 12 months after the January 20, 2026 grant date, following prior stockholder approval.
What are the terms of the stock options granted to the AVITA Medical (RCEL) director?
He received options for 16,133 shares of common stock at an exercise price of $3.77 per share. These options become exercisable on January 20, 2027 and expire on January 20, 2036, reflecting a long-dated equity incentive for the non-executive director.
Were the AVITA Medical (RCEL) director’s awards subject to stockholder approval?
Yes. The RSU grant and 16,133-stock-option grant were both subject to approval by AVITA Medical’s stockholders. That approval was obtained on June 3, 2026, after which the compensation awards, granted to non-executive directors, became effective under the disclosed terms.
Is this AVITA Medical (RCEL) Form 4 a buy or sell signal by the director?
The Form 4 shows compensation-related acquisitions, not market trading. The director received restricted stock units and stock options as awards, with no open-market purchases or sales reported, so it reflects routine equity compensation rather than an active trading decision.
AI-generated analysis. How Rhea-AI works. Not financial advice.
